← Leaderboards
Rajender R. Aparasu
South Dakota State University
$3,186,770
Attributed
$3,286,770
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $450K · FY2009–25$500K$375K$250K$125K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
AHRQ$2,252,622 · 5
NIH$1,034,148 · 3
By mechanism
R01$2,069,656 · 2
R56$449,906 · 1
R15$384,242 · 1
R13$200,000 · 1
R03$182,966 · 3
Top collaborators
- Holly M. Holmes4 shared
Others in their field
Top investigators on “Hospitalization”
- Larry Arthur$288,323,000
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$230,275,254
- Judith S. Currier · University Of California Los Angeles$223,149,861
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$221,207,102
- Lawrence Corey · Fred Hutchinson Cancer Center$217,829,567
- Daniel R Kuritzkes · Brigham And Women'S Hospital$179,610,394
Research focus
HospitalizationElderlyLeadPharmaceutical PreparationsMortalityAgingComplexProviderMedicalEvidence BaseDrug InteractionsHealthcareMorbidity - Disease RateCovid-19 PandemicEventAdverse Drug EventCollegeFundingClinicEducational TechnologyAdministratorBedsAreaChronic
Grant awards (17)
Deprescribing of Disease Modifying Agents in Older Adults with Multiple Sclerosis$397,090
R01 · FY2025 · HS · contact PI
Deprescribing of Disease Modifying Agents in Older Adults with Multiple Sclerosis$399,999
R01 · FY2024 · HS · contact PI
Geriatric Medication Safety Symposium$50,000
R13 · FY2024 · AG · contact PI
Deprescribing of Disease Modifying Agents in Older Adults with Multiple Sclerosis$399,999
R01 · FY2023 · HS · contact PI
Geriatric Medication Safety Symposium$50,000
R13 · FY2023 · AG · contact PI
Geriatric Medication Safety Symposium$50,000
R13 · FY2022 · AG · contact PI
Oral Adherence Trajectories Of Disease Modifying Agents And Associated Relapse Rates Among Patients With Multiple Sclerosis$25,815
R03 · FY2022 · HS · contact PI
Oral Adherence Trajectories Of Disease Modifying Agents And Associated Relapse Rates Among Patients With Multiple Sclerosis$74,185
R03 · FY2021 · HS · contact PI
Geriatric Medication Safety Symposium$50,000
R13 · FY2021 · AG · contact PI
Impact of Prescribing Cascade and Associated Drug Interaction in Alzheimer's Disease$449,906
R56 · FY2020 · AG · contact PI
SAFETY PROFILE OF ANTIMUSCARINICS IN ELDERLY DEMENTIA PATIENTS$384,242
R15 · FY2017 · AG · contact PI
Anticholinergics and Cognitive Decline in the Elderly with Depression$215,069
R01 · FY2015 · HS · contact PI
Anticholinergics and Cognitive Decline in the Elderly with Depression$215,069
R01 · FY2014 · HS · contact PI
Anticholinergics and Cognitive Decline in the Elderly with Depression$217,415
R01 · FY2013 · HS · contact PI
Anticholinergics and Cognitive Decline in the Elderly with Depression$225,015
R01 · FY2012 · HS · contact PI
Impact of Atypical Antipsychotic Use on Health Care Utilization in the Elderly$82,966
R03 · FY2009 · HS · contact PI
EVALUATION OF INAPPROPRIATE PSYCHOTROPIC USE IN ELDERLY$0
R03 · FY2000 · HS